EMT-associated resistance has been partially reversed in both in vitro and in vivo models through targeting TGF-β, Wnt/β-catenin pathways, and epigenetic modulators, thereby restoring tumor sensitivity to ALK inhibitors [84]. The gene discussed is ALK; the disease is neoplasm.